Details of the Drug Reposition

General Information of This Drug (ID: DMMT5Q4)

Drug Name
Amantidine   DMMT5Q4
Synonyms
adamantan-1-amine; 1-Adamantylamine; 1-Aminoadamantane; Adamantanamine; Adamantylamine; Aminoadamantane; Symmetrel; 1-Adamantanamine; 768-94-5; Amantidine; Pk-merz; Adamantamine; Symadine; 1-Adamantamine; Amantadinum; Amantadina; Amantadine [INN:BAN]; Amantadinum [INN-Latin]; Amantadina [INN-Spanish]; adamantan-1-ylamine; Gocovri; TCMDC-125869; 1-adamantaneamine; UNII-BF4C9Z1J53; 1-Aminotricyclo(3.3.1.1(sup 3,7))decane; NSC 341865; Tricyclo(3.3.1.13,7)decan-1-amine; HSDB 3202; tricyclo[3.3.1.1~3,7~]decan-1-amine; Tricyclo[3.
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Influenza virus infection DISPWU75 1E30-1E32 Approved [1]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Severe acute respiratory syndrome (SARS) DISYW14W 1D65 Investigative [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 209171.
2 Coronavirus envelope protein: current knowledge. Virol J. 2019 May 27;16(1):69.